preliminary findings in mcrpc for fractionated dose 177lu-psma-617
Published 4 years ago • 202 plays • Length 3:01Download video MP4
Download video MP3
Similar videos
-
5:30
fractionated dose 177lu-psma-617 in patients with mcrpc
-
1:48
expert discusses fractionated dose 177lu-psma-617 in mcrpc
-
1:35
vision: safety analysis of 177lu-psma-617 in mcrpc
-
1:00
is there are role for 177lu-psma-617 in earlier lines of treatment for mcrpc?
-
2:37
therap: cabazitaxel versus 177lu-psma-617 for mcrpc
-
11:01
lutetium-177: psma guided treatment | #prostatecancer | #markscholzmd | #pcri
-
6:26
how psma can change treatment decisions for prostate cancer | mark moyad, md, mph & mark scholz, md
-
3:30
radionuclide conjugates 225ac-j591 and 177lu-psma-i&t for mcrpc
-
5:27
177lu-psma-617 radionuclide therapy in mcrpc
-
2:04
phase i/ii trial of 177lu−j591 and 177lu−psma−617 in mcrcp
-
3:56
vision: 177lu-psma-617 in psma-positive mcrpc
-
6:45
177lu-psma-617 for prostate cancer: therap, vision, upfrontpsma and lutectomy
-
5:37
177lu-psma-617 for the early treatment of prostate cancer
-
1:24
luparp: 177lu-psma-617 and parp inhibitor combination for prostate cancer
-
1:37
recent advances in mhspc: 177lu-psma-617, propel and biomarker-directed strategies
-
0:28
177lu-psma-617 for metastatic castration-resistant prostate cancer
-
1:38
177lu-psma i&t for patients with psma-positive mcrpc
-
3:49
psma: prostate specific membrane antigen
-
0:56
analyzing responses to 177lupsma-617 in patients with metastatic crpc
-
11:07
phase 3 vision study of 177lupsma 617 for metastatic castration-resistant prostate cancer
-
5:47
phase i/ii dose-escalation study of 225ac-j591 in progressive mcrpc
-
7:39
psmafore phase 3 study